Adult Stem Cells Market (By Type: Autologous Adult Stem Cells, Allogeneic Adult Stem Cells; By Product & Services: Product, Services; By Indication; By Application; By End Use) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2024-2033

Adult Stem Cells Market Size and Trends

The global adult stem cells market was estimated at USD 12.37 billion in 2023 and it is expected to surpass around USD 35.86 billion by 2033, poised to grow at a CAGR of 11.23% from 2024 to 2033. Adult stem cells, also known as somatic stem cells, are undifferentiated cells found throughout the body that can differentiate into various cell types of their tissue of origin. Unlike embryonic stem cells, adult stem cells are found in mature tissues and have a more limited capacity for differentiation. However, they play a crucial role in the body's ability to repair and regenerate damaged tissues, making them a focal point for regenerative medicine and therapeutic research.

Key Pointers

• North America led the market with the largest market share of 44% in 2023.
• By Type, the allogeneic adult stem cells segment captured the maximum market share of 56% in 2023.
• By Type, the autologous adult stem cells segment is estimated to expand the fastest CAGR from 2024 to 2033.
• By Product & Services, the products segment dominated the market with a share of 80% in 2023
• By Indication, the bone and cartilage repair segment captured the maximum market share of 30% in 2023.
• By Application, the disease modeling segment generated the maximum market share of 30% in 2023.
• By End Use, the biopharmaceutical companies segment accounted for the largest share of 56% in 2023.

Adult Stem Cells Market Growth Factors

The adult stem cells market is experiencing robust growth driven by an increasing prevalence of chronic diseases like diabetes and cardiovascular disorders has heightened demand for effective treatments, enhancing the market's expansion. Advancements in stem cell research, including improved isolation and differentiation techniques, are accelerating therapeutic applications across various medical fields. Moreover, rising adoption of regenerative therapies, supported by promising clinical outcomes, continues to drive market growth. These factors collectively contribute to a promising outlook for the adult stem cells market, fostering innovation and expanding treatment possibilities in regenerative medicine.

Adult Stem Cells Market Trends

• Rapid Technological Advancements: Continuous innovations in stem cell isolation, culture, and differentiation techniques are enhancing therapeutic efficacy and expanding treatment applications.
• Increasing Adoption of Regenerative Therapies: Growing acceptance of adult stem cell therapies for treating various chronic conditions such as orthopedic injuries, cardiovascular diseases, and neurological disorders.
• Expanding Research and Development Initiatives: Rising investments in stem cell research by pharmaceutical companies, academic institutions, and government bodies to explore new therapeutic avenues and enhance clinical outcomes.
• Emergence of Personalized Medicine: Customized stem cell therapies tailored to individual patient profiles, improving treatment efficacy and patient outcomes.

Adult Stem Cells Market Challenges

• High Cost of Treatment: Stem cell therapies are often expensive due to the complexity of research, development, and clinical trials involved. This high cost limits accessibility to a broader patient population and poses financial challenges for healthcare systems.
• Limited Differentiation Potential: Compared to embryonic stem cells, adult stem cells have a more restricted capacity to differentiate into various cell types. This limitation may constrain their therapeutic applications in certain medical conditions requiring extensive tissue regeneration.
• Safety and Efficacy Concerns: Ensuring the safety and long-term efficacy of adult stem cell therapies remains a critical challenge. Variability in cell quality, potential for tumorigenicity, and immune rejection responses in recipients are ongoing concerns that need to be addressed through rigorous clinical trials and regulatory oversight.
• Complexity of Clinical Trials: Conducting robust clinical trials for adult stem cell therapies involves navigating complex regulatory pathways and demonstrating safety, efficacy, and reproducibility. The lengthy and costly trial processes can deter investment and slow down market growth.

What is the Contribution of North America to Adult Stem Cells Market?

North America dominated the global market, accounting for a 44% revenue share in 2023, driven by increased research and development activities focused on regenerative medicine solutions. Pharmaceutical companies, academic institutions, and biotechnology firms in the region are heavily investing in exploring the therapeutic potential of adult stem cells. These efforts aim to develop innovative treatments for conditions such as cardiovascular diseases, neurodegenerative disorders, and orthopedic injuries.

U.S. Adult Stem Cells Market Size 2024 to 2033

The U.S. adult stem cells market size was valued at USD 3.80 billion in 2023 and is expected to hit around USD 11.04 billion by 2033, poised to grow at a CAGR of 11.25% from 2024 to 2033. 

The U.S. market held a significant share of the North American market in 2023, primarily driven by the expanding field of stem cell therapy. Increasing numbers of clinical trials across various therapeutic areas, including oncology, orthopedics, and autoimmune diseases, are demonstrating the efficacy and safety of adult stem cell treatments.

The Asia Pacific market is experiencing the fastest growth, driven by significant research and development efforts in adult stem cell technology. Countries like Japan, South Korea, and China are at the forefront, investing heavily in advanced technologies and innovative therapies. These nations focus on developing cutting-edge treatments for various diseases, including cardiovascular, neurological, and autoimmune disorders.

Type Insights

The allogeneic adult stem cells segment dominated the market with a share of 56% in 2023, driven by continuous innovation and contributions from leading market players. Companies are actively developing advanced therapies and expanding their product portfolios to address diverse medical conditions. For example, in September 2022, Bristol Myers Squibb and Century Therapeutics formed a strategic alliance to develop therapies using allogeneic cells derived from induced pluripotent stem cells (iPSCs). This collaboration leverages Century's advanced iPSC-derived allogeneic cell therapy technology with Bristol Myers Squibb's extensive expertise in oncology drug development and cell therapy.

The autologous adult stem cells segment is projected to exhibit the fastest CAGR over the forecast period, driven by increasing clinical trials and research endeavors. This personalized approach, utilizing a patient's own stem cells, minimizes rejection risks and enhances treatment efficacy. Several ongoing clinical trials are exploring autologous therapies for conditions such as cardiovascular diseases, neurological disorders, and orthopedic injuries. Significant investments in research and development are accelerating the advancement of innovative therapies, further propelling market expansion and offering promising solutions for various medical conditions.

Product & Services Insights

The products segment dominated the market with a share of 80% in 2023, driven by several key factors. Within this segment, the cells and cell lines category has emerged as a significant revenue generator, bolstering market growth. Numerous market participants are actively pursuing untapped opportunities in this domain through strategies such as new product development and business expansion. For instance, in January 2024, Cellcolabs AB, a spin-off from the prestigious Karolinska Institute specializing in both research-grade and Good Manufacturing Practice (GMP) mesenchymal stem cells (MSCs), entered a strategic partnership with REPROCELL Inc., a pioneering Japanese company focused on induced pluripotent stem cells (iPSCs).

The services segment is experiencing robust growth, driven by increasing demand for stem cell banking, processing, and storage services. This expansion is fueled by heightened awareness of stem cell therapies and their potential benefits. Service providers are investing in advanced technologies and robust infrastructure to ensure high-quality, reliable services. Additionally, collaborations with healthcare institutions and ongoing research efforts are enhancing service capabilities and scope, contributing to overall market growth.

Indication Insights

The bone and cartilage repair segment led the market with a share of 30% in 2023, driven by advancements in regenerative medicine. Innovations in stem cell therapies are offering new, effective treatment options for conditions such as osteoarthritis, fractures, and cartilage injuries. Adult stem cells, particularly mesenchymal stem cells (MSCs), are increasingly utilized due to their ability to differentiate into bone and cartilage tissues, promoting natural healing and regeneration. For instance, a review published in the Journal of Translational Medicine in 2022 discussed the modification of MSCs for cartilage-targeted therapy, highlighting the significance of MSC homing for effective MSC-based cartilage repair.

The inflammatory and immunological diseases segment is anticipated to grow at the fastest CAGR during the forecast period, driven by the increasing recognition of stem cell therapies' potential in treating autoimmune disorders and inflammatory conditions. Adult stem cells, particularly mesenchymal stem cells (MSCs), have demonstrated promise in modulating immune responses and reducing inflammation. Clinical trials and research studies are exploring their efficacy in conditions such as rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease. Advances in understanding immune system interactions and refining cell therapy techniques are propelling market expansion, opening new avenues for effectively managing chronic inflammatory and immunological diseases.

Application Insights

The disease modeling segment held the largest share of 30% in 2023, driven by technological advancements and increased research activities. Adult stem cells, particularly induced pluripotent stem cells (iPSCs), serve as valuable tools for modeling various diseases in laboratory settings. They enable researchers to study disease mechanisms, screen potential drug candidates, and develop personalized medicine approaches. The application of iPSCs in disease modeling is expanding across a wide range of conditions, including genetic disorders, neurodegenerative diseases, and cardiovascular disorders. This growth is enhancing our understanding of disease pathophysiology and accelerating the development of targeted therapies.

The tissue engineering segment is expected to grow significantly over the forecast period, driven by substantial investments in regenerative medicine and advanced biotechnology. Adult stem cells, particularly mesenchymal stem cells (MSCs), play a pivotal role in tissue regeneration and repair. Innovations in biomaterials, 3D bioprinting, and scaffold technologies are enhancing the efficacy of stem cell-based tissue engineering therapies. These advancements enable the creation of functional tissues for applications in orthopedics, cardiovascular repair, and wound healing.

End Use Insights

The biopharmaceutical companies segment accounted for the largest share of 56% in 2023 and is projected to grow at the fastest CAGR of 11.53%, driving innovation and commercialization of stem cell-based therapies. These companies are heavily investing in research and development to harness the therapeutic potential of adult stem cells across various medical applications. They collaborate with academic institutions and clinical research organizations to advance clinical trials and regulatory approvals. For instance, in August 2021, Gilead Sciences subsidiary Kite announced the acquisition of Appia Bio Inc., a biotechnology company. The partnership aims to jointly explore and develop new hematopoietic stem cell (HSC)-derived therapies specifically targeting hematopoietic cancers (haematological malignancies).

The research institutes segment is expanding as institutions focus on pioneering advancements in stem cell research. These institutes drive innovation through fundamental research, clinical trials, and collaborations with biotechnology firms and healthcare providers. They play a critical role in advancing knowledge of stem cell biology, therapeutic applications, and translational research efforts. With increased funding and interdisciplinary collaborations, research institutes are shaping the future of regenerative medicine and contributing to the growth and development of the market.

Who are the Top Manufactures in Adult Stem Cells Market?

• Thermo Fisher Scientific, Inc
• STEMCELL Technologies
• Osiris Therapeutics
• Vericel Corporation
• ZenBio, Inc.
• Stempeutics Research
• Fate Therapeutics, Inc.
• BrainStorm Cell Therapeutics Inc.
• Celgene Corporation
• Stemedica Cell Technologies, Inc.

Recent Developments

• In April 2024, Gamida Cell Ltd. received FDA approval for Omisirge, their allogeneic cell therapy. The approval allows its use in adult and pediatric patients aged 12 and older with hematologic malignancies undergoing umbilical cord blood transplantation post-myeloablative conditioning. The therapy aims to accelerate neutrophil recovery and reduce infection risk.
• TrophiCell, a spin-out from the University of Liverpool, showcased innovative applications of adult mesenchymal stem cells (MSCs) for medical purposes in February 2024.
• EPROCELL announced in May 2023 its intention to launch Contract Development and Manufacturing Organization (CDMO) services specializing in Advanced Therapy Medicinal Products (ATMPs) derived from mesenchymal stem cells (MSCs). This initiative is developed in collaboration with Histocell.

Adult Stem Cells Market Segmentation:

By Type

• Autologous Adult Stem Cells
• Allogeneic Adult Stem Cells

By Product & Services

• Product
  • Kits, Media, & Reagents
  • Cells & cell lines
    • Hematopoietic
    • Mesenchymal
    • Neural
    • Epithelial/Skin
    • Others
• Services

By Indication

• Bone and Cartilage Repair
• Cardiovascular Diseases
• Inflammatory and Immunological Diseases
• Liver diseases
• Cancer
• GvHD
• Others

By Application

• Therapeutics
• Disease Modeling
• Drug Development & Discovery
• Toxicology Studies
• Biobanking
• Tissue Engineering
• Others

By End Use

• Biopharmaceutical Companies
• Research Institutes
• Hospitals & Clinics

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa